Bruce E. Ivins, der Regierung biodefense Wissenschaftler, der mit den tödlichen Anthrax-Postsendungen von 2001, gestanden, um von der massiven Bundesausgabe in der Furcht-gefüllten Nachmahd jener Tötungen finanziell zu gewinnen, die Los Angeles Zeiten verbunden wird, hat erlernt.

Ivins wird als Coerfinder auf zwei Patenten für einen genetisch ausgeführten Anthraximpfstoff, Bundesaufzeichnungen darstellen verzeichnet. Separat wird Ivins auch als Coerfinder auf einer Anwendung verzeichnet, um einen Zusatz für verschiedene biodefense Impfstoffe zu patentieren.

Ivins, 62, gestorben Dienstag in einem offensichtlichen Selbstmord in Maryland. Bundesbehörden hatten seinen Rechtsanwalt informiert, daß die kriminellen Aufladungen, die auf den Postsendungen bezogen wurden, eingeordnet würden.

Als Coerfinder eines neuen Anthraximpfstoffs, gehörte Ivins zu denen in der Linie, zum der Patentabgaben, wenn das Produkt gekommen war zu vermarkten, entsprechend einem Hauptleiter zu sammeln mit der Angelegenheit vertraut.

Das Produkt hatte auf Laborregalen bis den Sept. geschmachtet. 11 Angriffe und die Anthrax-Postsendungen, nachdem die Bundesbeamten liefen, um Impfstoffe und Antidote gegen möglichen biologischen Terrorismus zu speichern.

Eine San Francisco-Bereich Biotechnologiefirma, VaxGen, gewann einen Bundeskontrakt wert $877.5 Million, um Reihen des neuen Impfstoffs zur Verfügung zu stellen. Der Vertrag war zuerst zugesprochen unter der Gesetzgebung, die vom Präsidenten Bush gefördert wurde, angerufen Project BioShield.

Ein Hauptleiter, der mit der Angelegenheit vertraut war, sagte, daß, als Zustand seinem Kaufens des Impfstoffs von der Armee, VaxGen zustimmt Verkauf-in Verbindung stehenden Erträgen des Anteiles mit den Erfindern hatte.

„Irgendein Anteil würde mit den Erfindern,“ geteilt worden sein, sagte den Hauptleiter, der anonym wegen der Vertragsvertraulichkeit sprach. „Ivins würde gestanden sein, um 10 von den Tausenden Dollar, aber nicht Millionen zu bilden.“

Zwei Jahre nachdem VaxGen der Vertrag zugesprochen wurde, wurde der Pakt beendet, als die Firma nicht seine Reihen auf Zeitplan liefern könnte. Der Endpunkt bedeutete, daß VaxGen nicht zahlend war, noch waren Ivins und seine Coerfinder.

Ivins auch wurde als einer von zwei Erfindern eines anderen biodefense-in Verbindung stehenden Produktes verzeichnet, das Bundesförderung gewonnen hat.

Entsprechend ihrer noch-schwebenden Anwendung für US patent, the inventors hoped the additive would bolster certain vaccines’ capacity to prevent infections “from bioterrorism agents.”

From December 2002 to December 2003, the Pentagon’s Defense Advanced Research Projects Agency committed $12 million for additional testing of the experimental additive. That research money was designated for Coley Pharmaceutical Group, which was developing the additive. The company was acquired last fall by Pfizer Corp.

Samuel C. Miller, a Georgetown Law Center professor who is a patent-law expert, said that the extent to which Ivins stood to gain from the two issued patents or the one that remains pending hinges on the terms of the related contracts.

“It will depend on the business arrangements that are in place,” Miller said.

On Friday, colleagues and critics of Ivins pondered the mystery within the mystery: If Ivins did it, why?

One former senior official with Ivins’ employer, the U.S. Army Medical Research Institute of Infectious Diseases, whom the FBI questioned at length about Ivins, said he believed his former colleague wanted more attention — and resources — shifted to biological defense.

“It had to have been a motive,” said the former official, who suspects that Ivins was the culprit. “I don’t think he ever intended to kill anybody. He just wanted to prove ‘Look, this is possible.’ He probably had no clue that it would aerosolize through those envelopes and kill those postal workers.”

Of the five people killed by the mailings, two worked for the U.S. Postal Service in the Washington, D.C., area; one was a photo editor in Palm Beach County, Fla.; another was a hospital supply provider in New York City; and the last known victim was a 94-year-old woman in Connecticut.

Several letters were addressed to prominent people — two U.S. senators and NBC news anchor Tom Brokaw, for example.

For nearly 30 years, Ivins served far from the limelight, a PhD microbiologist who drew a civil servant’s pay while handling some of the most deadly pathogens on Earth — live spores of anthrax.

The deadly mailings of anthrax-tainted envelopes transported Ivins from the backwater of government scientific research at Ft. Detrick, Md., to the center of the nation’s fledgling war on terrorism. It also spurred multibillion-dollar national security initiatives.

Ivins was thrust into the federal investigation of the mailings as well. He helped the FBI analyze anthrax recovered from a letter addressed to then-Senate Majority Leader Tom Daschle (D-S.D.).

He also played a lead role in helping a private company, BioPort, win regulatory approval to continue making the vaccine required for U.S. service personnel deployed to Iraq, Afghanistan and other regions.

From 2000 to early 2002, Ivins and two colleagues from USAMRIID helped BioPort resolve problems related to the potency of the vaccine. Because of those and other manufacturing difficulties, production had been suspended. The efforts of Ivins and his colleagues helped BioPort win FDA approval to resume production.

At a Pentagon ceremony on March 14, 2003, Ivins and two colleagues from USAMRIID were bestowed the Decoration of Exceptional Civilian Service, the highest honor given to nonmilitary employees of the Defense Department.

“Awards are nice,” Ivins said in accepting the honor. “But the real satisfaction is knowing the vaccine is back on line.”

The Times sought earlier this year to obtain annual financial disclosure statements filed by Ivins with his employer. USAMRIID spokeswoman Caree Vander Linden said last month that Ivins had filed financial reports exempt from disclosure under the Freedom of Information Act.

Ivins’ apparent suicide and the Justice Department’s decision to bring criminal charges against him were first reported Thursday night by The Times. On Friday, Ivins’ lawyer, Paul F. Kemp, defended his client and said that Ivins had cooperated fully with the FBI.

“We assert his innocence in these killings, and would have established that at trial,” Kemp said, implicitly confirming that Ivins had been about to be formally charged. “The relentless pressure of accusation and innuendo takes its toll in different ways on different people. . . . In Dr. Ivins’ case, it led to his untimely death.”

Kemp did not respond to telephone calls and e-mails for this article.

Times researcher Janet Lundblad contributed to this report.